High-dose cyclophosphamide without stem cell rescue in immune-mediated necrotizing myopathies
Citation Manager Formats
Make Comment
See Comments
This article has a correction. Please see:

Article Information
- Received February 10, 2017
- Accepted in final form May 30, 2017
- First Published July 11, 2017.
Author Disclosures
- Christopher A. Mecoli, MD, MHS,
- Arash H. Lahouti, MD,
- Robert A. Brodsky, MD,
- Andrew L. Mammen, MD, PhD and
- Lisa Christopher-Stine, MD, MPH
- Christopher A. Mecoli, MD, MHS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Arash H. Lahouti, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Robert A. Brodsky, MD,
Alexion, Achillion, apellis
NONE
Alexion
Blood, editorial board
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Alexion
NIH, NHLBI
NONE
AA/MDS foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Andrew L. Mammen, MD, PhD and
aTYR pharmaceuticals advisory board Biogen advisory board
NONE
NONE
Experimental Neurology, Editorial Board, 2013- Arthritis and Rheumatism, Editorial Board, 2014-
I am a patent holder on a commercial test for anti-HMGCR antibodies that is licensed to INOVA diagnostics; I receive no financial compensation for this since moving to the NIH in 2014.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Andrew Mammen: (1) NIAMS/NIH, 1-ZIA-AR041203, Principle Investigator, 2014-present (2) NIAMS/NIH, 5-K08-AR054783, Principle Investigator, 2008-2012 Jennifer Mammen (wife of Andrew Mammen): (1) NIDDK/NIH, 5-K23-DK095954, Principle Investigator, 2014-present
NONE
NONE
NONE
I am a patent holder on a commercial test for anti-HMGCR antibodies that is licensed to INOVA diagnostics; I received financial compensation for this only prior to joining the NIH in 2014.
I am a patent holder on a commercial test for anti-HMGCR antibodies that is licensed to INOVA diagnostics; I received financial compensation for this only prior to joining the NIH in 2014.
NONE
NONE
NONE
- Lisa Christopher-Stine, MD, MPH
(1)Novartis (2) Medimmune (3) Walgreen's/Optioncare (4) Mallinckrodt (5) Idera Pharmaceuticals (6) Octapharma (7) Corbus
NONE
(1)Novartis, honorarium (2) Medimmune, honorarium (3) Walgreen's/Optioncare, honorarium (4) Mallinckrodt, honorarium (5) Idera Pharmaceuticals, honorarium (6)Octapharma, honorarium
NONE
(1) Detection of HMGCoA reductase (HMGCR) Antibodies in Patient Sera (Inova Diagnostics)
NONE
NONE
(1) Mallinckrodt Pharamaceuticals
NONE
NONE
NONE
(1) NuFactor (2) Option Care (3) IgG America (4) MedProRx (5) CSL Behring
(1) NHLBI ?Inflammation and Coronary Endothelial Function (HL120905) DSMB Chair (2) NHLBI ?Inflammatory pathogenesis of coronary atherosclerosis in HIV? (HL14023), DSMB Chair.
NONE
Donald B. and Dorothy L. Stabler Foundation
NONE
NONE
(1) Detection of HMGCoA reductase (HMGCR) Antibodies in Patient Sera, Royalties, 2012
NONE
NONE
(1) McAloon and Friedman, P.C. 2014,2015 (2) Shaub, Ahmuty, Citrin, and Spratt, LLP 2014 (expert witness) (3) The Chartwell Law Offices, LLP (expert witness) (4) PK Law (expert witness) (5) Bodie, Dolina, Hobbs, Friddell & Grenzer, P.C.(expert witness)
- From the Johns Hopkins University School of Medicine (C.A.M., A.H.L., R.A.B., A.L.M., L.C.-S.), Baltimore; and National Institute of Health (A.L.M.), Bethesda, MD.
- Correspondence to Dr. Christopher-Stine: lchrist4{at}jhmi.edu
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodiesIago Pinal-Fernandez, Christopher A. Mecoli, Maria Casal-Dominguez et al.Neurology, October 08, 2019 -
Article
Inflammatory myopathy with myasthenia gravisThymoma association and polymyositis pathologyNaohiro Uchio, Kenichiro Taira, Chiseko Ikenaga et al.Neurology: Neuroimmunology & Neuroinflammation, December 24, 2018 -
Article
Identification of distinctive interferon gene signatures in different types of myositisIago Pinal-Fernandez, Maria Casal-Dominguez, Assia Derfoul et al.Neurology, August 21, 2019 -
Article
Clinical course and treatment of anti-HMGCR antibody–associated necrotizing autoimmune myopathySudarshini Ramanathan, Daman Langguth, Todd A. Hardy et al.Neurology - Neuroimmunology Neuroinflammation, April 02, 2015